Escobar Ruling Helps Genentech Beat Avastin FCA Suit
The Third Circuit on Monday nixed a False Claims Act suit accusing Genentech Inc. of defrauding Medicare by concealing side effects of its blockbuster cancer drug Avastin, saying a whistleblower didn't...To view the full article, register now.
Already a subscriber? Click here to view full article